Bifikafusp alfa

• Target:

  Interleukin

• Related Pathways:

  Immunology/Inflammation

• Bioactivity:

  Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein combining human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin, and has demonstrated anticancer activity [1].

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1957239-90-5